Process for preparing pemetrexed di potassium and its hydrates
US-2015259348-A1 · Sep 17, 2015 · US
Pemetrexed dipotassium formulations
US9789113B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9789113-B2 |
| Application number | US-201515310451-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 23, 2015 |
| Priority date | Jun 30, 2014 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof. The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising pemetrexed dipotassium nonahydrate characterized by X-ray powder diffraction pattern containing at least 5 characteristic 2θ° diffraction angle peaks selected from the XRPD peak set of 5.0, 12.5, 17.2, 20.8, 22.4, 25.7, 26.9 and 27.9±0.20 2θ°, and a pharmaceutically acceptable amount of an excipient, wherein the pharmaceutical composition having moisture content less than 2% w/w.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Ortho-condensed systems · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9789113B2 cover?
- The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof. The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.
- Who is the assignee on this patent?
- Shilpa Medicare Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).